Kronos Bio (KRON) Competitors $1.01 -0.03 (-2.42%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$1.01 0.00 (0.00%) As of 01/31/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends KRON vs. CMPS, CGC, AMRN, ZYBT, GOSS, CADL, MOLN, FULC, LRMR, and FDMTShould you be buying Kronos Bio stock or one of its competitors? The main competitors of Kronos Bio include COMPASS Pathways (CMPS), Canopy Growth (CGC), Amarin (AMRN), Zhengye Biotechnology (ZYBT), Gossamer Bio (GOSS), Candel Therapeutics (CADL), Molecular Partners (MOLN), Fulcrum Therapeutics (FULC), Larimar Therapeutics (LRMR), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry. Kronos Bio vs. COMPASS Pathways Canopy Growth Amarin Zhengye Biotechnology Gossamer Bio Candel Therapeutics Molecular Partners Fulcrum Therapeutics Larimar Therapeutics 4D Molecular Therapeutics Kronos Bio (NASDAQ:KRON) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, valuation, profitability, risk, dividends, earnings and analyst recommendations. Does the media favor KRON or CMPS? In the previous week, Kronos Bio and Kronos Bio both had 2 articles in the media. COMPASS Pathways' average media sentiment score of 0.65 beat Kronos Bio's score of 0.44 indicating that COMPASS Pathways is being referred to more favorably in the news media. Company Overall Sentiment Kronos Bio Neutral COMPASS Pathways Positive Do institutionals & insiders hold more shares of KRON or CMPS? 64.1% of Kronos Bio shares are owned by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are owned by institutional investors. 24.4% of Kronos Bio shares are owned by insiders. Comparatively, 4.3% of COMPASS Pathways shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is KRON or CMPS more profitable? COMPASS Pathways has a net margin of 0.00% compared to Kronos Bio's net margin of -867.66%. COMPASS Pathways' return on equity of -63.85% beat Kronos Bio's return on equity.Company Net Margins Return on Equity Return on Assets Kronos Bio-867.66% -64.55% -48.18% COMPASS Pathways N/A -63.85%-51.97% Does the MarketBeat Community believe in KRON or CMPS? COMPASS Pathways received 40 more outperform votes than Kronos Bio when rated by MarketBeat users. Likewise, 80.26% of users gave COMPASS Pathways an outperform vote while only 65.63% of users gave Kronos Bio an outperform vote. CompanyUnderperformOutperformKronos BioOutperform Votes2165.63% Underperform Votes1134.38% COMPASS PathwaysOutperform Votes6180.26% Underperform Votes1519.74% Which has stronger valuation and earnings, KRON or CMPS? Kronos Bio has higher revenue and earnings than COMPASS Pathways. COMPASS Pathways is trading at a lower price-to-earnings ratio than Kronos Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKronos Bio$6.29M9.69-$112.67M-$1.43-0.71COMPASS PathwaysN/AN/A-$118.46M-$2.20-1.96 Do analysts prefer KRON or CMPS? Kronos Bio presently has a consensus price target of $1.63, suggesting a potential upside of 60.89%. COMPASS Pathways has a consensus price target of $33.60, suggesting a potential upside of 679.58%. Given COMPASS Pathways' stronger consensus rating and higher possible upside, analysts plainly believe COMPASS Pathways is more favorable than Kronos Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kronos Bio 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33COMPASS Pathways 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, KRON or CMPS? Kronos Bio has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.27, meaning that its stock price is 127% more volatile than the S&P 500. SummaryCOMPASS Pathways beats Kronos Bio on 9 of the 15 factors compared between the two stocks. Get Kronos Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for KRON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRON vs. The Competition Export to ExcelMetricKronos BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.55M$6.87B$5.57B$9.14BDividend YieldN/A2.90%5.31%3.99%P/E RatioN/A4.4258.4413.87Price / Sales9.69321.141,257.3981.09Price / CashN/A73.5045.9637.70Price / Book0.375.275.124.71Net Income-$112.67M$136.98M$111.17M$224.24M7 Day Performance-2.88%-0.59%2.38%-0.17%1 Month Performance6.32%0.18%3.20%0.60%1 Year Performance-6.48%7.68%24.70%20.43% Kronos Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRONKronos Bio3.486 of 5 stars$1.01-2.4%$1.63+60.9%-10.6%$61.55M$6.29M-0.71100Short Interest ↑Positive NewsCMPSCOMPASS Pathways2.1383 of 5 stars$3.49+2.3%$33.60+862.8%-61.8%$238.79MN/A-1.59120CGCCanopy Growth1.2488 of 5 stars$2.18-3.1%$3.50+60.6%-57.4%$237.49M$220.27M-0.441,029Upcoming EarningsShort Interest ↓News CoveragePositive NewsAMRNAmarin0.4011 of 5 stars$0.56+0.7%N/A-49.0%$229.15M$306.91M-6.20360ZYBTZhengye BiotechnologyN/A$4.73+0.9%N/AN/A$223.10M$189.75M0.00N/AGOSSGossamer Bio4.2446 of 5 stars$0.96-3.8%$9.20+856.4%+18.3%$217.97MN/A-3.01180Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageCADLCandel Therapeutics3.3728 of 5 stars$6.66-13.4%$19.00+185.3%+443.8%$216.32M$120,000.00-3.8560Positive NewsGap DownMOLNMolecular Partners0.8821 of 5 stars$5.36-7.8%N/A+11.7%$216.13M$7.84M-2.49180Gap DownFULCFulcrum Therapeutics1.413 of 5 stars$3.96-0.5%$9.33+135.7%-45.2%$213.60M$2.81M-12.77100News CoveragePositive NewsLRMRLarimar Therapeutics1.7527 of 5 stars$3.34+2.8%$20.43+511.6%-33.7%$213.13MN/A-2.9030Analyst ForecastNews CoverageFDMT4D Molecular Therapeutics3.2557 of 5 stars$4.58-2.1%$38.56+741.8%-67.5%$211.73M$20.72M-1.61120Short Interest ↓ Related Companies and Tools Related Companies CMPS Competitors CGC Competitors AMRN Competitors ZYBT Competitors GOSS Competitors CADL Competitors MOLN Competitors FULC Competitors LRMR Competitors FDMT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KRON) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kronos Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kronos Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
